Rx (Prescription Medicine)
USD $ 45.00
Pacliaqualip 30mg 注射剂是一种重要的药物，用于治疗多种类型的癌症。其活性成分为紫杉醇，是一种强效的化疗药物，属于紫杉烷类药物。紫杉醇通过干扰微管的正常功能来发挥作用，微管是细胞分裂的关键组成部分。通过稳定这些微管，紫杉醇阻止癌细胞分裂和增殖，最终导致其死亡。这种作用机制使其能够有效治疗多种恶性肿瘤。
Pacliaqualip 30mg 注射剂适用于卵巢癌、乳腺癌和非小细胞肺癌的治疗。也可与其他化疗药物联合使用，用于某些卡波西肉瘤的治疗。剂量和治疗时长由主治医生根据具体的癌症类型、分期、患者的整体健康状况以及对疗法的反应来确定。通常以静脉注射方式由医护人员给予。
与 Pacliaqualip 30mg 注射剂相关的常见不良反应可能包括骨髓抑制（导致血细胞计数下降）、脱发、神经损伤（神经病变）、恶心、呕吐、过敏反应。患者还可能出现疲劳、肌肉和关节疼痛以及心律改变。如出现任何不寻常或严重的不良反应，应立即向医生报告。Pacliaqualip 30mg 注射剂应储存在室温，避光保存，并放在儿童不易触及的地方。
| Medicine Form | |
|---|---|
| Rx Status | |
| Medicine Type | |
| Molecule | |
| Brand Name | |
| Strength |
其他品牌的 Paclitaxel 30 mg — 同一活性成分且强度相同，但来自不同制造商。
医学审核
Renu Meena, B.Pharm
Medical Content Writer
Renu Meena is an experienced Medical Content Writer with a strong foundation in pharmacy practice. She holds a Bachelor of Pharmacy (B.Pharm) degree from Rajasthan University of Health Sciences (RUHS), Jaipur, and is registered with the Rajasthan State Pharmacy Council (Reg. No. 55661). With 4+ years of experience across clinical pharmacy and medical content development, she creates evidence-based content for medicines, diseases, and patient education. Her work is shaped by a strong understanding of pharmacovigilance and regulatory standards, including ICH guidelines, GVP modules, ICD-10/11, and safety reporting requirements. Renu focuses on making complex medical information simple, accurate, and useful for readers while maintaining high quality and compliance.
